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This study evaluated the 12-month retention rate of third agents in HAART (highly active anti-retroviral therapy) regimens in
routine clinical practice in a Canadian HIV clinic. This is a descriptive retrospective database analysis of HIV-positive patients
naı ¨ve to antiretroviral therapy (ART). The study included male and female HIV patients]18 years of age at HAART initiation
date, seen in routine consultation at the Maple Leaf Medical Clinic (MLMC),Toronto, Ontario, Canada. Data were extracted from
the MLMC database for the period of September 1st, 2003 to August 31st, 2010 for patients who commenced a protease
inhibitor (PI), a non-nucleoside reverse-transcriptase inhibitor (NNRTI), or an integrase inhibitor (II) -based regimen in
combination with two nucleoside reverse transcriptase inhibitors (NRTI). Demographic and baseline disease characteristics were
extracted and include age, gender, disease duration, baseline HIV-1 RNA count, CD4 cell count, and hepatitis B and C co-infection
status at baseline. A total of 722 patients were included in the analysis.The primary outcome of the study was the proportion of
HIV patients remaining on their initial third agent (PI, NNRTI, or II) at one year post-treatment initiation. For therapies used by
more than 10% of patients (efavirenz [EFV]315, atazanavir [ATV]104, lopinavir [LPV]162, as other agents were used but
in limited numbers), the percentage of patients still on the initial third agents at one year was 77%, 64% and 62%, respectively.
In addition, viral load (VL) was less than 50 copies/mL in 95% of EFV, 79% of ATVand 76% of LPV patients at one year.The rate of
discontinuation at 12 months from EFV, ATV, and LPV due to efficacy (i.e. lack of virologic suppression) or safety (i.e. adverse
events) were 15.56%, 19.23%, and 19.75% respectively. In a clinical practice setting, the majority of patients treated with HAART
regimens were maintained on therapy at one year and were able to suppress their viral load consistently. Of those reported
here, EFV resulted in the best retention rate and viral suppression overall.
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